Sanofi
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SNW2.F | SANOFI.NS | PFE | BIIB | GLAXO.BO | 0QYQ.IL | |
|---|---|---|---|---|---|---|
| Market cap | 99.68B | 77.75B | 175.50B | 37.61B | 423.63B | 217.96B |
| P/E (TTM) | 24.3 | 21.3 | 44.0 | 110.2 | 44.4 | 40.2 |
| Forward P/E | 9.5 | 19.0 | 10.6 | 15.6 | 36.9 | — |
| Price/book | 1.4 | 9.4 | 2.1 | 2.0 | 24.8 | 10.3 |
| Dividend yield | 5.10% | 3.56% | 5.59% | — | 1.75% | 3.81% |
| 1-year change | −3.32% | −27.30% | +23.90% | +62.35% | +6.17% | +40.64% |
| Today | +0.97% | −2.17% | +2.63% | +2.22% | −1.26% | +1.70% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All SNW2.F news ›Eyes on Sanofi more than ever
By raising its full-year guidance, Sanofi is sending a positive signal to the market. It still needs to follow that up with tangible results, which will not be easy. Published on 11/02/2026 at 03:20 am EST It is true that, like its peers,…
Sanofi expands Canadians' COVID-19 vaccine choice with availability of Nuvaxovid®for the 2026-2027 respiratory season
Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will be available in 10 provinces and one territory for the fall 2026-2027 respiratory season A protein-based, non-mRNA vaccine that has demonstrated high efficacy against symptomatic…
Regeneron's Sanofi Windfall Drives A 19.5% Beat, But The Retinal Franchise Is Still Treading Water
New Upgrade: Dedicated Screeners for Stocks & ETFs The call also flagged several items unlikely to repeat: On a GAAP basis, EPS rose a more muted 35% to $18.45. The main drag was much lower gains on securities, which fell to $60 million…
Polycystic Kidney Disease Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and ROA Trends | Otsuka Pharma, Sanofi S.A, Reata Pharma, Galapagos N.V, Janssen Pharma
Albany New York October 28 2026 As per DelveInsight s assessment globally Polycystic Kidney Disease pipeline constitutes 8 key companies continuously working towards developing 10 Polycystic Kidney Disease treatment therapies analysis of…
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO). In a report released today, Sachin Jain from Bank of America Securities…
Regeneron expects 2027 R&D expense to rise by a mid-teens percentage while recording a $1B Sanofi upfront payment in Q4
"We're pleased to report another quarter of strong performance, driven by outstanding commercial execution and a large and diverse pipeline that is continuing to deliver on its promise." (CEO Leonard ... Earnings Call Insights: Regeneron…
Sanofi and Regeneron Advance Dupixent Coformulation in Key Phase 1 Study
Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. The trial evaluates a coformulated Dupixent plus berahyaluronidase alfa injection versus standard Dupixent alone. The goal is to see if…
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has climbed to $919.58, up 12%.…
Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts
BREAKING: Nasdaq Futures Fall Over 2% As Amazon, Intel Fuel AI Rout The company's Sanofi (SNY)-partnered immunology drug, Dupixent, brought in $6.54 billion vs. forecasts for $6.15 billion in sales. Sanofi records global sales of Dupixent…
Sanofi lifts profit outlook on strong Dupixent sales
The French drugmaker reported third-quarter business earnings of €3.55 per share, beating analyst estimates by €2.04. Revenue rose 16.2% year over year to €14.44B, exceeding expectations by €1.12B. Sales from pharmaceutical launches surged…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com30
- seekingalpha.com17
- markets.businessinsider.com6
- theglobeandmail.com5
- firstwordpharma.com4
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.